Advertisement

Topics

Trastuzumab biosimilar from Prestige accepted for review by EMA

07:14 EDT 14 Jun 2019 | Generics and Biosimilars Initiative

Singapore-based Prestige BioPharma (Prestige) announced on 28 May 2019 that the regulatory submission for its proposed trastuzumab biosimilar Tuznue (HD201) had been accepted by the European Medicines Agency (EMA).

Original Article: Trastuzumab biosimilar from Prestige accepted for review by EMA

NEXT ARTICLE

More From BioPortfolio on "Trastuzumab biosimilar from Prestige accepted for review by EMA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...